Due to the 14-day incubation requirement for compendial sterility, this is often the last data available when testing BioPharmaceutical products for release or stability. So turnaround time pressure has always been an inherent part of sterility testing. This pressure has become more acute with the emergence of ATMPs, particularly autologous cell therapies which are often given to patients before traditional testing results can be obtained. Eurofins BioPharma Product Testing has responded to the demand for faster sterility results by streamlining…